More on BTAI

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-1,066.7% Growth)
- Ratings (5.0 Score)

Upcoming Events

- Earnings (11/14/25 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

BioXcel Therapeutics (NQ:BTAI)
Delayed: 1.48 -0.13 (8.07%)
Prev. Close $1.61  
Open$1.56 
52 Wk High$ 
52 Wk Low$ 
Day High$1.60 
Day Low$1.47 
P/E N/A  
EPS$ 
Volume2,896,063 

Friends, Peers and Foes (?): AMST, PLTR, TVGN TVGNW (more...)

Mar 5, 2026 07:00 AM BioXcel reports positive phase 2 results for BXCL501 in opioid withdrawal
Mar 5, 2026 07:00 AM BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
Feb 19, 2026 07:00 AM BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
Feb 12, 2026 07:06 AM Form 8-K BioXcel Therapeutics, For: Feb 12
Feb 12, 2026 07:01 AM BioXcel Therapeutics advances IGALMI commercialization for at-home use
Feb 12, 2026 07:00 AM BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
Feb 9, 2026 04:13 PM Form SCHEDULE 13G/A BioXcel Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC
Feb 6, 2026 05:01 PM Form 8-K BioXcel Therapeutics, For: Feb 04
Jan 20, 2026 07:01 AM Form 8-K BioXcel Therapeutics, For: Jan 20
Jan 20, 2026 07:01 AM BioXcel submits application to expand IGALMI use to at-home setting
View All Articles

Entities mentioned with BTAI

View All Entities